The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

被引：13
作者：
Moon H. [1 ]
Noh W.C. [2 ]
Kim H.-A. [2 ]
Kim E.-K. [2 ]
Park K.W. [3 ]
Lee S.S. [4 ,5 ]
Choi J.H. [1 ]
Han K.W. [1 ]
Byun B.H. [1 ]
Lim I. [1 ]
Kim B.I. [1 ]
Choi C.W. [1 ]
Lim S.M. [1 ]
机构：
[1] Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75, Nowon-ro, Nowon-gu, Seoul
[2] Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[3] Department of Radiology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[4] National Radiation Emergency Medical Center, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[5] Department of Pathology, Korea Cancer Center Hospital, Seoul
来源：
Nuclear Medicine and Molecular Imaging | 2016年 / 50卷 / 3期
关键词：
Breast cancer; Dual phase; Estrogen receptor; Human epidermal growth factor receptor 2; Positron emission tomography; Retention index;
D O I：
10.1007/s13139-016-0412-2
中图分类号：
学科分类号：
摘要：
Purpose: This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers. Methods: A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen. Results: RImean was significantly higher in ER (−) (median, 16.2; IQR, 10.8–21.0) or HER-2 (+) (median, 16.1; IQR, 10.7–21.6) tumors than in ER (+) tumors (median, 9.9; IQR, 5.5–15.3) or HER-2 (−) tumors (median, 10.5; IQR, 5.5–16.1). However, there were no significant differences of SUVmax or RImax according to the ER or HER-2 status. There were no significant differences of any PET parameters between PR (+) and PR (−) tumors. Based off ROC curve analyses, RImean predicted the ER (+) tumors (AUC, 0.699; p = 0.006), and HER-2 (+) tumors (AUC, 0.674; p = 0.022), but not the PR (+) tumors. However, neither SUVmax nor RImax predicted ER (+), PR (+), or HER-2 (+) tumors. Conclusions: Retention index of SUVmean can reflect the ER and HER-2 status of breast cancers. Higher retention index of SUVmean might associate with lower ER expression and higher HER-2 expression. © 2016, Korean Society of Nuclear Medicine.
引用
收藏
页码：246 / 254
页数：8
相关论文
共 59 条
  • [1] Jung K.W., Won Y.J., Kong H.J., Oh C.M., Et al., Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010, Cancer Res Treat, 45, 1, pp. 1-14, (2013)
  • [2] Ahn S.H., Korean Breast Cancer S. Clinical characteristics of breast cancer patients in Korea in 2000, Arch Surg, 139, 1, pp. 27-30, (2004)
  • [3] Key T.J., Verkasalo P.K., Banks E., Epidemiology of breast cancer, Lancet Oncol, 2, 3, pp. 133-140, (2001)
  • [4] Sariego J., Zrada S., Byrd M., Matsumoto T., Breast cancer in young patients, Am J Surg, 170, 3, pp. 243-245, (1995)
  • [5] Harris L., Fritsche H., Mennel R., Norton L., Et al., American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, 33, pp. 5287-5312, (2007)
  • [6] Groheux D., Giacchetti S., Rubello D., Al-Nahhas A., Et al., The evolving role of PET/CT in breast cancer, Nucl Med Commun, 31, 4, pp. 271-273, (2010)
  • [7] Danforth D.N., Aloj L., Carrasquillo J.A., Bacharach S.L., Et al., The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer, Breast Cancer Res Treat, 75, 2, pp. 135-146, (2002)
  • [8] Groheux D., Moretti J.L., Baillet G., Espie M., Et al., Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer, Int J Radiat Oncol Biol Phys, 71, 3, pp. 695-704, (2008)
  • [9] Fuster D., Duch J., Paredes P., Velasco M., Et al., Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures, J Clin Oncol, 26, 29, pp. 4746-4751, (2008)
  • [10] Schwarz-Dose J., Untch M., Tiling R., Sassen S., Et al., Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose, J Clin Oncol, 27, 4, pp. 535-541, (2009)
123456